# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-25-013973
Filing Date
2025-04-15
Accepted
2025-04-15 16:39:35
Documents
18
Period of Report
2025-05-23

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | ny20042463x1_pre14a.htm iXBRL | PRE 14A | 1769147
3 |  | logo_nektar.jpg | GRAPHIC | 14135
4 |  | ny20042463x1_barchart01.jpg | GRAPHIC | 173557
5 |  | ny20042463x1_pvpchart01x1.jpg | GRAPHIC | 212153
6 |  | ny20042463x1_pvpchart02.jpg | GRAPHIC | 176356
| Complete submission text file | 0001140361-25-013973.txt |  | 4349598

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | INLINE XBRL TAXONOMY EXTENSION - SCHEMA | nktr-20250523.xsd | EX-101.SCH | 2117
20 | EXTRACTED XBRL INSTANCE DOCUMENT | ny20042463x1_pre14a_htm.xml | XML | 330097

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-24006 | Film No.: 25840085
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)